Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5054 - Anti-PD1 inhibitors: assessment of proper use, efficacy and economic impact in daily practice

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP;  Immunotherapy

Presenters

Aurélien Gobert

Citation

Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375

Authors

A. Gobert1, A. Jaeger2, L. Taillade1, N. Osman2, D. Lassoued1, C. Mateescu1, P. Maingon3, P. Tilleul2, J. Spano1, A. Bellanger2

Author affiliations

  • 1 Medical Oncology Unit, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 2 Pharmacy Unit, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 3 Radiotherapy Unit, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
More

Resources

Abstract 5054

Background

Nivolumab, an anti-PD-1 inhibitor, has been approved in France in treatment of first-line BRAF wild-type advanced melanoma and of advanced non-small cell lung cancer after platinum-based chemotherapy, with an approximate monthly processing cost of €5,550 per patient. The objective of our study was to evaluate efficacy and correct use of anti-PD1 antibodies in daily practice since its approvals.

Methods

This retrospective study was conducted between July 2015 and December 2016 on 62 patient files at the Pitié-Salpêtrière hospital, using patient medical records and Multidisciplinary Medical Board (MMB) software. According to the Summary of Product Characteristics (SPC), the correct use of nivolumab required compliance with indications, a WHO status

Results

Sixty patients were treated for lung cancer: 38 patients (62%) with adenocarcinoma, 14 (22%) with squamous cell carcinoma and 8 (13%) with large cell lung cancer. At the cut-off analysis, 28 patients (47%) had a progressive disease, 20 (32%) were still receiving treatment and 41(65%) were still alive, with a median follow-up of 6.5 months (0,3 to 17.7 months). Thirteen patients received more than 10 injections and 13 received less than 5 injections. The correct use of nivolumab was observed in 45 patients (73%), 12 patients had a WHO status of 2, 1 patient had a WHO status of 3, and 4 patients received concomitant corticosteroids. The poor utilization of treatment for these 17 patients (27%) totaled 149 injections, costing about €410,000 for a total of €1,615,000 of expenditures using this treatment. Survival rates were not statistically different in these patients compared to those respecting SPC criteria (53% versus 70%; p = 0.2).

Conclusions

Although a high cost of inappropriate use of nivolumab, there was no significant difference in survival rates in these patients. These preliminary findings highlight the differences between study populations and daily practice, reflecting willingness of practitioners to give patients access to innovative treatments. Cost effectiveness and efficacy/tolerance data will be updated at the meeting presentation to better determine treatment criteria in daily practice.

Clinical trial identification

Legal entity responsible for the study

Assistance Publique - Hôpitaux de Paris

Funding

None

Disclosure

J-P. Spano: Received fees and has been member of advisory board of Bristol-Myers Squibb, MSD and Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.